We published our discovery of EB1, the first in class Type-II MNK1/2 inhibitor. With funding from Planes Complemetarias, we are testing its efficacy in combination with approved therapies. Following our discovery of the role of ITGB3 in intercellular communication we have identified new inhibitors that target this process and prevent metastatic diseases progression in animal models. This is pending publication upon patent protection. The pathology department is leading the implementation of Digital Pathology Network in the Catalan health system (DigiPatICS) and we have published the first results. Following our discovery that the gap junction protein Cx43 induces tunneling nanotubes, which regulate malignancy and therapy-resistance, we initiated an ISCIII grant to study this phenomena, and continued an AECC grant to identify therapeutic peptides that inhibit these cell-cell communication networks in cancer. We have also initiated work on the pannexin 1 channel protein in this setting.
eCOREs
